Retatrutide

Retatrutide is a triple receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, representing a distinct pharmacological approach in metabolic research. Currently under Phase 3 clinical investigation by Eli Lilly, Retatrutide is structurally and mechanistically differentiated from semaglutide, which acts as a single GLP-1 receptor agonist, and tirzepatide, a dual GIP/GLP-1 agonist. The additional glucagon receptor activity in Retatrutide is hypothesised to amplify energy expenditure through hepatic and thermogenic pathways, offering a unique triple-agonist profile not previously available in a single molecule. Published Phase 2 clinical data, reported in the New England Journal of Medicine, demonstrated substantial reductions in body weight over a 48-week treatment period across multiple dosing cohorts. Researchers investigating incretin biology and multi-receptor agonism consider Retatrutide a critical compound for understanding how simultaneous activation of three metabolic receptors modulates glucose homeostasis, lipid metabolism, appetite regulation, and energy balance. The compound's triple-agonist mechanism provides a novel research tool for studying receptor crosstalk and the synergistic effects of combined incretin and glucagon signalling in metabolic disease models.